Linaglipton Duyou Tablet 2.5/500 milligrams
Linagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Seongwon Adcock Pharmaceutical Co., Ltd.
MFDS item code 202001419 · Approved 2020.02.28
This product's status changed to Expired on 2025.02.28. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used in conjunction with diet and exercise to improve blood glucose control in adults with type 2 diabetes. It can be administered to patients who find it difficult to control their blood glucose levels with monotherapy when they first receive diabetes medication. It can also be used when switching from a combination of Linagliptin and Metformin. In cases where blood glucose is not sufficiently controlled with insulin and Metformin combination therapy, this drug can be administered alongside insulin to enhance therapeutic effects. Lastly, if blood glucose control remains challenging with a combination of Metformin and Empagliflozin, this medication can be used together with Empagliflozin for effective blood glucose management. This drug is used to improve blood glucose control in patients with type 2 diabetes.
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine should be taken twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no previous history of antidiabetic drug treatment who have difficulty achieving adequate glycemic control with monotherapy, the starting dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should take as the initial dose the same doses of linagliptin and metformin they were previously taking. 3. Patients unable to achieve adequate glycemic control with combination therapy with insulin and metformin: The initial dose of this medicine should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Patients in whom the medicine should be administered with caution). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine. Any change in the treatment regimen for type 2 diabetes may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 1. Patients in whom the medicine is contraindicated).
This medication has the potential for serious side effects such as lactic acidosis, so caution is required. Lactic acidosis is a rare but life-threatening condition, and patients with impaired kidney or liver function, severe infection, dehydration, or heart disease should not use this medication. Additionally, it should not be administered to those with allergies to any of its components, nor in cases of type 1 diabetes, diabetic ketoacidosis, or acute alcohol intoxication. It is advisable for pregnant or breastfeeding women to avoid using this medication. This medication carries a risk of hypoglycemia; therefore, it is important to closely monitor blood glucose levels when taking it in combination with hypoglycemic agents such as insulin or sulfonylureas, and dosage adjustments may be necessary. Elderly patients with reduced kidney function or situations where renal function changes are expected should undergo regular kidney function tests, and treatment should be adjusted or discontinued as necessary. When iodine contrast agents are used for radiographic examinations, this medication should be discontinued before and after the examination, and kidney function should be assessed. Moreover, this medication should be discontinued for a certain period before and after surgery. Possible side effects include gastrointestinal disturbances, abdominal pain, diarrhea, vomiting, and, in rare cases, pancreatitis, skin rashes, and severe joint pain. If these symptoms occur, immediate consultation with healthcare professionals is required. Vitamin B12 deficiency may occur, so it is advisable to regularly check vitamin B12 levels when using this medication for an extended period. This medication may interact with other drugs, so if you are taking any other medications, it is important to inform your healthcare provider, especially if using drugs that may affect kidney function. Lastly, this medication is not recommended for children under 10 years of age, and its effects on driving or operating machinery are not known, so caution should be exercised.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture, so it should be stored in a tightly closed container. Furthermore, it is important to store it at room temperature between 1°C and 30°C to maintain the drug's efficacy.
Bright yellow, double convex, oval film-coated tablets
60 tablets / PTP [10 tablets / PTP packaging X 6]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Linagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Seongwon Adcock Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Anguk Pharm Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kukje Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
International Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.